Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Empagliflozin benefits in patients with heart failure and preserved ejection fraction

Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF ≥50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Effect of empagliflozin versus placebo on clinical outcomes according to LVEF category.

References

  1. Talha, K. M. & Butler, J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin. Cardiol. 45, S31–S39 (2022). A review of the history of classification of heart failure with mildly reduced and preserved ejection fraction and advances in their treatment.

    Article  Google Scholar 

  2. Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021). This paper reports the main findings of the EMPEROR-Preserved clinical trial.

    Article  CAS  Google Scholar 

  3. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020). This paper reports the main findings of the EMPEROR-Reduced clinical trial.

    Article  CAS  Google Scholar 

  4. Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895–e1032 (2022). A review article that presents the latest comprehensive clinical guidelines on managing heart failure from the major US cardiology associations.

    Google Scholar 

  5. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015). This paper reports the main findings of the EMPA-REG OUTCOME clinical trial.

    Article  CAS  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Anker, S. D. et al. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. Nat. Med. https://doi.org/10.1038/s41591-022-02041-5 (2022).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Empagliflozin benefits in patients with heart failure and preserved ejection fraction. Nat Med 28, 2480–2481 (2022). https://doi.org/10.1038/s41591-022-02050-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02050-4

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing